Gain Therapeutics (GANX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

GANX Gain Therapeutics

Watchlist

1.790
+0.080+4.68%

Close Dec 6 16:00 ET

1.790
0.0000.00%

Post 20:01 ET

47.48MMarket Cap-1672P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Cuts Target Price to $7
Moomoo NewsDec 6 05:34 ET · Ratings
Gain Therapeutics Price Target Announced at $7.00/Share by Roth MKM
Dow JonesDec 6 04:07 ET · Ratings
Gain Therapeutics Initiated at Buy by Roth MKM
Dow JonesDec 6 04:07 ET · Ratings
Promising Preclinical Data and Financial Position Support Buy Rating for Gain Therapeutics
TipRanksNov 25 06:55 ET · Ratings
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5
Moomoo NewsNov 20 13:32 ET · Ratings
Chardan Capital Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $6
Moomoo NewsNov 19 03:36 ET · Ratings

Comments

Stock_Drift

Nov 14 18:01

After Hours Ticks. 7:00pm

$Mercurity Fintech (MFH.US)$ $Freightos (CRGO.US)$ $1847 Holdings (EFSH.US)$ $MediciNova (MNOV.US)$ $Despegar.com (DESP.US)$ $NextPlat (NXPL.US)$ $Legacy Education (LGCY.US)$ $Gain Therapeutics (GANX.US)$ $Red Cat Holdings (RCAT.US)$ $Siyata Mobile (SYTA.US)$ $Innovation Beverage Group (IBG.US)$ $Greenidge Generation (GREE.US)$ $The Arena Group (AREN.US)$
📊⚡️📊

Stock_Drift

Oct 30 17:49

After Hours Ticks. 6:48pm

$Gain Therapeutics (GANX.US)$ $Orion Group (ORN.US)$ $Nextracker (NXT.US)$ $Alphatec (ATEC.US)$ $Remitly Global (RELY.US)$ $1847 Holdings (EFSH.US)$ $Carvana (CVNA.US)$ $Junee (JUNE.US)$ $Tenon Medical (TNON.US)$ $Aditxt (ADTX.US)$ $CPS Technologies (CPSH.US)$ $Root Inc (ROOT.US)$
📊⚡️📊

Jaguar8

Oct 7 06:01

NEWS

$Gain Therapeutics (GANX.US)$
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
Gain Therapeutics presented new preclinical data for GT-02287 at the Society for Neuroscience 2024 conference. The data demonstrates disease-modifying activity in both GBA-1 and idiopathic Parkinson's disease models. Key findings include:
1. Persistent rescue of motor and cognitive function after GT-02287 discontinuation
2. Improved mitochondrial function and neuroprotection in GBA1-Parkins...

Trytosaveabit

Sep 30 06:37

Update

$Gain Therapeutics (GANX.US)$ Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
Gain Therapeutics, Inc. Mon, Sep 30, 2024, 7:00 AM 7 min read
Gain Therapeutics, Inc.
GT-02287 Increases Peripheral GCase Activity
GT-02287 Demonstrates CNS Exposure